The company was founded in 2004 under the name Pharmalink AB and is based in Stockholm, Sweden.
Timeline
2017
Pharmalink changes name to Calliditas Therapeutics
Publication of results from Phase 2b study in The Lancet
End-of-Phase 2 meetings with FDA and EMA
2016
Preparations for end-of-Phase 2 meetings with FDA and EMA
Obtains orphan designation for Nefecon in Europe
Publication of meta-analysis related to change in urine protein as a surrogate endpoint with regards to IgA nephropathy, Tufts Medical Center, 2016
2015
Invited to work with the Kidney Health Initiative (American Society of Nephrology) to identify surrogate endpoints in IgA nephropathy
Receives financing from existing investors to progress clinical process towards Phase 3
Announces initial results from Phase 2b trial and achieves the primary endpoint in a planned interim analysis
2014
Nefecon core patents are granted in the US, Europe, China and Hong Kong
2013
Investinor joins the existing investors to finance the completion of the Phase 2b study
2012
Owners including Industrifonden and Bengt Julander finance the launch of the Phase 2b (NEFIGAN) trial
2004 – 2011
The Phase 2a study is completed with positive results
Calliditas obtains orphan designation for Nefecon in the United States
Nefecon becomes the lead product candidate
Calliditas gains exclusive rights to the formulation technology to develop and manufacture Nefecon Stiftelsen
Industrifonden invests in the company